NSPR icon

InspireMD

2.70 USD
+0.02
0.75%
At close Mar 27, 4:00 PM EDT
1 day
0.75%
5 days
-3.57%
1 month
-19.64%
3 months
0.37%
6 months
-1.82%
Year to date
1.50%
1 year
18.42%
5 years
-70.65%
10 years
-100.00%
0
Funds holding %
of 7,390 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

7% more funds holding

Funds holding: 28 [Q3] → 30 (+2) [Q4]

1% more capital invested

Capital invested by funds: $33.2M [Q3] → $33.4M (+$192K) [Q4]

0.5% more ownership

Funds ownership: 48.24% [Q3] → 48.74% (+0.5%) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for NSPR.

Financial journalist opinion

Based on 5 articles about NSPR published over the past 30 days

Neutral
GlobeNewsWire
1 day ago
InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference
MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced management will present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 8:00AM Eastern Time / 5:00AM Pacific Time. A live audio webcast and replay of the presentation may be accessed for 90 days on the “News & Events” section of the company's website at: https://www.inspiremd.com/en/events/ About InspireMD, Inc. InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes.
InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference
Neutral
Seeking Alpha
2 weeks ago
InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript
NSPR (NASDAQ:NSPR ) Q4 2024 Earnings Conference Call March 12, 2025 8:30 AM ET Company Participants Marvin Slosman - CEO Craig Shore - CFO Shane Gleason - CCO Webb Campbell - IR, Gilmartin Group Conference Call Participants Adam Maeder - Piper Sandler Frank Takkinen - Lake Street Capital Markets Richard Nesbitt - InspireMD Operator Hello and welcome to InspireMD's fourth quarter 2024 earnings conference call. [Operator instructions].
InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript
Neutral
Zacks Investment Research
2 weeks ago
InspireMD, Inc. (NSPR) Reports Q4 Loss, Tops Revenue Estimates
InspireMD, Inc. (NSPR) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.16 per share a year ago.
InspireMD, Inc. (NSPR) Reports Q4 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
2 weeks ago
InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results
MIAMI, March 12, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights: Engaged with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. ahead of an anticipated first half 2025 approval Announced approval of and enrolled first patients in the CGUARDIANS II pivotal study of the CGuard Prime carotid stent system for use during TCAR procedures Established headquarters in Miami, Florida, to optimally support the anticipated U.S. commercial launch of CGuard Prime in the first half of 2025, if approved Achieved quarterly revenue and unit records of $1.95M and 3.5K respectively in served markets Marvin Slosman, CEO of InspireMD, commented: “2024 was a year of tremendous progress at InspireMD.
InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results
Neutral
GlobeNewsWire
4 weeks ago
InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results
MIAMI, Feb. 26, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m.
InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results
Neutral
GlobeNewsWire
1 month ago
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to six new non-executive employees in the aggregate amount of 138,442 shares of restricted stock outside of InspireMD's 2021 Equity Compensation Plan, with a grant date as of February 5, 2025, as an inducement material to the employees and the director entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of InspireMD, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with InspireMD, pursuant to Nasdaq Listing Rule 5635(c)(4).
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
GlobeNewsWire
1 month ago
InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures
TOLEDO, Ohio and MIAMI, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime Carotid Stent System for the prevention of stroke related to carotid stenosis, and NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, today announced that, pursuant to a previously announced strategic outsourcing partnership, the companies are working together to conduct the CGUARDIANS II pivotal study of InspireMD's CGuard Prime™ 80 cm carotid stent system for use in Transcarotid Artery Revascularization (TCAR) procedures.
InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures
Neutral
GlobeNewsWire
1 month ago
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI, Feb. 04, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to one new non-executive employee in the amount of 18,000 shares of restricted stock outside of InspireMD's 2021 Equity Compensation Plan, with a grant date as of January 7, 2025, as an inducement material to the employee entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4).
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Positive
Zacks Investment Research
3 months ago
NSPR Stock May Gain as First Patient Enrolls in CGUARDIANS II Study
InspireMD announces the first patient enrolment in the CGUARDIANS II clinical trial.
NSPR Stock May Gain as First Patient Enrolls in CGUARDIANS II Study
Neutral
GlobeNewsWire
3 months ago
InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)
Study represents a significant step forward in Company's mission to serve the broadest set of physician and patient needs with best-in-class CAS and TCAR solutions Study represents a significant step forward in Company's mission to serve the broadest set of physician and patient needs with best-in-class CAS and TCAR solutions
InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)
Charts implemented using Lightweight Charts™